DIGISTAIN CLINICAL VALIDATION STUDY PUBLISHED IN ‘BREAST CANCER RESEARCH & TREATMENT’

London, UK – 24 January 2024. A clinical validation study of Digistain in 801 patients with ER-positive, HER2-negative early breast cancer (median follow-up 12.7 years) was published in Breast Cancer Research and Treatment. The study reports the prognostic performance of the Digistain Prognostic Score; please see the publication for full results.

Digistain logo

Digistain nominated for the EIT Awards 2026

Digistain has been nominated for the EIT Awards 2026 in the Venture Award category. The Venture Award recognises organisations combining strong commercial potential with meaningful

Supported by:

royal society logo
NIHR logo
cancer research uk logo
BIVDA logo

Subscribe to leading news and insights

To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.